Member Info for spinnaker

Grezz, I make that about 20p below LSE Friday close. Bear in mind the % rise on Monday's ASX is relative to Friday's ASX close.

I expect the price to drop a bit now and without further news will be geared to gold price.

I must say I am very pleased and fairly relaxed about my GGP investment at present. I just wish I had bought more than 100 shares at £5 a couple of weeks ago.

Hello Doc and all long term holders. Great allegorical post Doc and I have always enjoyed your level headed and understated posts on this board.

For me too this was one of the first shares I purchased back in early 2020 and over the next year or two built up a large holding being a majority of my liquid capital and some knowledge and was convinced that interferon B was going to be world changing.

It has been a very expensive and finally disappointing lesson. I did sell most of my shares just before de-listing for the price of a few pints but totally forgot about those in my SIPP so I am still a holder but have no hope at all of any recompense. Having said that I did have capital losses to set against profits from the sale of my mothers flat last year so that saved me a couple of thousand. It wasn't only SNG that I invested in during lockdown period. Nearly all turned out to be major failures including NCYT which was my second largest holding. Looking back now I think I was rather swept up in the whole Covid thing although fortunately had no close relatives who died or had to be ventilated.

My lack of investing nous has been well and truly exposed mostly due to either buying at the wrong time or not selling when I should have and holding far too long. From an investing point of view it has been all so depressing over the last few years made even more depressing by our appalling governments the general madness and violence in the world together with the fact that every company and person seems out to scam us.

I'll raise a glass to you Doc and the other believers. Good luck for the future to all.

Spinnaker

All very sad!

Thanks to everyone for the sensitive posts that will be support to all. It feels like Synairgen has been my baby for the last two years and that probably applies to a lot of the individuals posting here. Doc is right that health and family are the most important things in life and I am lucky to have three young grandchildren to enjoy.

Like many, I was so convinced of the science and the probity of the BoD that I invested far too much as a percentage of my liquid assets and ended up with a relatively high average of about 130p. In hindsight the 30,000 shares I bought in the fund raise contributed to that but I wanted to contribute to enabling a safe treatment to reduce the mayhem we were all suffering and so don't regret that, just upset that SNG001 has not made it to the hospitals and chemists. No doubt greed also came into it or I would have sold a chunk near 200p and this is a very big lesson to have learned rather late in life.

After being in mourning yesterday I spent today with a chainsaw and splitting axe at my sailing club which temporarily took out some of the frustration and sadness and so am now totally knackered with blisters on my hands.

Still holding all and unsure what to do. Will probably wait for RM to give an interview or make a statement.

Best wishes to all the very decent people who have contributed here over the past two years.

Spinnaker

Mr Costs. You are confused. SNG001 was never in Activ 3. We are still in Activ2 which is for non-hospitalised patients but have moved from phase 2 to phase 3.

Best Spinnaker

I'll go with Matterhorn and Doc83. To avoid possible argument as to bias, the results should not be released until after the last person to fill in their questionnaire after 90 days of their first dose has done so.
Best to all
Spinnaker

In my experience of commercial property rent reviews (which may or may not be the same), an Independent Expert will prepare his own valuation, doing his own research using whatever information he can glean from publicly or privately available resources and his own experience. He may or may not invite representations and counter-reps from the parties but is not bound or limited by any such representations.

An Arbitrator however is a legal or quasi legal position and he is bound by and limited to the evidence presented in the submissions of the parties. An Arbitrator is not being appointed here, it is an Expert as far as I understand.

Spinnaker

Thanks from me too for the well informed responses on this paper linked by xv and another.
Spinnaker

Hi xviolet

I see nobody has replied to your post and interesting link. The board seems to be fairly hyped up awaiting news on P3 not surprisingly.

I have had a quick look at the pre-print findings and must say I am a bit unsure about the meaning and relevance to SNG001 vs Omicron. Also how the method of testing undertaken by this research team compares to the in-vitro testing in respect of Delta and Omicron being undertaken by Synairgen at the moment.

Can any of the scientists here please shine some light on this?

Many thanks

Spinnaker

Great letter D-D-R-R

A large cheer to Massive Ray and Docdaneeka. I think you can tell that we are all going to have a comfortable and expectant Christmas.

Yes, we long term holders will be annoyed that we didn't sell a chunk more than a year ago at over £2 and then buy back sub £1 but we are finally at a tipping point that was first expected after P2, then last Christmas I had hoped P3 would be done and dusted before this winter set in. Still, Covid and we are mostly still here, probably even Nolupus, though he hasn't posted recently and are avidly awaiting potentially life changing results in both healthcare and our finances on successful P3 results.

Happy Christmas to all and good health and cheer for 2022 especially all the staff and directors at Synairgen.

Spinnaker

Well I just saw the email from Primary Bid. I wasn't expecting a fund raise now and certainly not at 14.5p. I tried to buy some more through Primary Bid but the offer has closed.
Oh well, let's see what tomorrow brings. It will be interesting. I doubt there will be any immediate news since if it was good and about to be released then surely they would have RNS'd that before the fund raise.
Best to all
Spinnaker

I'm not sure if this has been posted but I didn't know about it.

https://science.thewire.in/the-sciences/everything-you-need-to-know-molnupiravir-merck-new-anti-covid-drug/

Ivermectin and Favipiravir are being trialled under PRINCIPLE. 7,000 volunteers already. It looks like the MHRA are under orders to have a pill or two ready asap. Trial not due to conclude until next year but given what has happened with Molnupavir I wouldn't be so sure.
Price and convenience seem to be favoured by UK gov, perhaps above safety. Not sure this is fair comment in terms of Ivermectin which seems to have a good safety record of course but efficacy data still awaited.

There does not appear to be any sell off of SNG at the moment, the price remaining amazingly stable. The current interest in treatments should give some more airtime to Synairgen.

Best to all

Spinnaker

Good luck Woodie. Stress isn't helpful so sit back and relax for a bit and hope you are able to post in a few weeks time.

Spinnaker

I am still here and will definitely be up for a meet in due course.
With the recent SP increases Synairgen has single-handedly revived my portfolio which is otherwise looking rather sad.
I'm very pleased that we have finally got back above the placing price.
I'm desperately sad that our product will not now be contributing to saving lives this year but still hopeful that next year will be a new and transforming chapter.

Best to all.

Spinnaker

As far as I recall, the original budget was in the region of £30,000 per person recruited but I don't suppose all of that would go to the hospital.

Spinnaker

To be honest I am so far down the pan with most of the shares mentioned in this thread that the surface still seems a long long way away.
Still holding Synairgen strong though and hoping for great things.

Spinnaker

Good news from Kansas.

I don't know if I am mistaken but I got the impression from Dr Castro that the P2 trial for Synairgen had been 'completed' whereas the other trials had been 'filled'. If the distinction was intended it may well mean that Synairgen is a month or so ahead of other trial drugs. This would certainly be good news and potentially give us a few weeks initially with less competition as you hoped Doc. The big 'if' still remains of course as noted by other valued posters.

Best to all.

Spinnaker

Woodie

One thing for sure is the next variant that becomes the most prevalent will by definition be more easily transmissible than Delta which is 90% plus of current new infections in UK. We just don't know whether it will be more injurious.
Also as far as the UK and other highly vaccinated nations are concerned the next variant of concern may be better able to evade antibodies produced by current vaccinations. I expect that this would allow higher viral loads and therefore assist transmissibility making it more likely that such a variant will become the most prevalent.

All these things point to SNG001 being of major assistance in helping prevent severe disease no matter how the virus mutates. The important aspect is that our treatment will assist the body's natural defence and not specifically target a particular virus or variant .

The sooner we get the results of our P3 trial the sooner our company's product can be brought to the fight.

Up Synairgen!

Spinnaker

Jez, from what I have just read in the New York Times

https://www.nytimes.com/live/2021/08/11/world/covid-delta-variant-vaccine?campaign_id=154&emc=edit_cb_20210811&instance_id=37709&nl=coronavirus-briefing®i_id=169216731&segment_id=66001&te=1&user_id=cc5424f0040cce45b83c504bc701f767#world-health-organization-drugs-virus

all three drugs are existing approved drugs and are being repurposed with the hope they will be helpful for Covid.

Again, WHO are still looking for existing drugs to be repurposed presumably because these are a lot cheaper and quicker to trial than novel drugs that have not yet been approved for any purpose.

Spinnaker